Home›Companies›Biotech & Pharma›Dash Bio

Dash Bio, Inc.

Provides laboratory sample analysis services for drug developers.

Updated Nov 10, 2026·Latest SEC filing Jul 14, 2026·Suggest an edit

About Dash Bio

Dash Bio is a private company based in Boston, Massachusetts, incorporated in 2024 in Delaware. It has reported $47,120,998 raised in three offerings on Form D since October 2024. Its chief executive is David Johnson.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jun 15, 2026Jul 14, 2026$30,000,022fully sold9$3.3MEquityRule 506(b)Form D ↗
Jun 13, 2025Jun 26, 2025$10,999,976target not set12$916KEquityRule 506(b)Form D ↗
Oct 2, 2024Oct 17, 2024$6,121,000target not set15$408KEquityRule 506(b)Form D ↗
Total, three offerings$47,120,998

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Dash Bio's Form D filed Jul 14, 2026.

David Johnson
David Johnson
Chief Executive Officer and director
Alexander Tallett
Alexander Tallett
Chief Operating Officer and director
AS
Andy Smith
Director

Sources

  1. SECDash Bio, Inc. filing history
  2. CompanyAbout Dash Bio
  3. CompanyDash Bio Series A announcement